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Abstract
New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening
settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18
and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk
HPV infections in an area with a high background risk of cervical cancer, where women aged 23–65 years are targeted for
cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in
Denmark serving the whole of Copenhagen. All samples were stored in SurePath media. In total, 5,072 samples were tested
with cobas, Hybrid Capture 2 High Risk HPV DNA test (HC2) and liquid-based cytology. Of these, 27% tested positive on
cobas. This proportion decreased by age, being 43% in women aged 23–29 years and 10% in women aged 60–65 years. HC2
assay was positive in 20% of samples, and cytology was abnormal ($ atypical squamous cells of undetermined significance)
for 7% samples. When only samples without recent abnormalities were taken into account, 24% tested positive on cobas,
19% on HC2, and 5% had abnormal cytology. The proportion of positive cobas samples was higher than in the ATHENA trial.
The age-standardized cobas positivity vs. cytology abnormality was 3.9 in our study and 1.7 in ATHENA. If in Copenhagen
the presently used cytology would be replaced by cobas in women above age 30 years, an extra 11% of women would
based on historical data be expected to have a positive cobas test without an underlying cervical intraepithelial lesion grade
3 or worse. Countries with a high prevalence of HPV infections should therefore proceed to primary HPV-based cervical
screening with caution.
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Introduction
The higher sensitivity for high-grade cervical intraepithelial
neoplasia (CIN) of Human Papillomavirus (HPV) testing com-
pared with cytology [1] could protect more women from
developing cervical cancer [2,3]. Because of this, it is expected
that HPV testing will slowly replace cytology in primary cervical
screening. So far, HPV DNA testing has been implemented into
primary cervical screening e.g. in the USA, Mexico, and the
Spanish region of Castile and Leon, whereas the Netherlands
made a recommendation for primary screening in 2011. In other
countries, HPV testing has been used in triage of women aged
$30 years with atypical squamous cells of undetermined
significance (ASCUS) for colposcopy, and in surveillance after
CIN treatment.
For several years, HPV DNA testing has been synonymous with
Qiagen’s digene Hybrid Capture 2H High Risk HPV DNA test
(HC2; Qiagen, Gaithersburg, MA, USA). The HC2 assay has
been extensively studied all over the world in randomized
controlled trials and numerous split-sample studies [1,4,5].
Because of this, it is widely considered a standard HPV DNA
assay [6]. Recently, more HPV assays have become commercially
available. The designs of these assays differ from that of HC2 in
terms of the targeted viral genes and of the testing methods.
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Accordingly, their clinical characteristics may differ from those of
HC2 and need to be evaluated in a variety of settings [7].
The cobasH HPV Test (cobas; Roche Diagnostics, Pleasanton,
CA, USA), approved by the USA Food and Drug Administration
in 2011, is a fully automated real-time polymerase chain reaction
(PCR) assay. The assay batches up to 94 samples together with
positive and negative controls. It allows for a differentiated positive
result distinguishing HPV genotypes 16 and 18 separately next to
the bulk of 11 other high-risk and one possibly high-risk HPV
genotypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) [8].
Because genotypes 16 and 18 alone cause about 70% of all cervical
cancers [9], use of HPV16/18 genotyping has been proposed as
a triage procedure for referral of HPV-positive, cytology-normal
women for colposcopy [10]. The largest study to date evaluating
the cobas test has been ATHENA, a split-sample study undertaken
in 46,887 women aged $21 years presenting for routine cervical
screening at 61 clinical sites in the USA [11]. In ATHENA, cobas
testing in women aged $25 years was almost 40% more sensitive
than cytology for detection of $CIN3 (crude sensitivities 92% vs.
53%) [12]. Moreover, referral for colposcopy of cytology-normal/
cobas-positive women with HPV16 or HPV18 had a good positive
predictive value for detecting $CIN3 [13]. Several smaller studies
evaluated the use of cobas HPV testing in women recommended
for further follow-up owing to abnormal screening tests [14–18].
All of these studies were undertaken using samples stored in
PreservCyt, universal collection medium, or specimen transport
medium.
In the present population-based split-sample study, we com-
pared cobas testing with liquid-based cytology (LBC) and HC2 on
consecutive samples from a large cervical cytology laboratory
covering all of Copenhagen, Denmark. The population from this
area is well-screened but has a high background risk of cervical
cancer. In 1958–62, prior to the start of screening, the age-
standardized incidence of cervical cancer in Copenhagen was 35
per 100,000 (world standard population) [19]. The Copenhagen
samples in the present study were stored in SurePathH media (BD
Diagnostics–TriPath, Burlington, NC, USA).
Materials and Methods
Study Population
In Denmark, women aged between 23 and 49 years without
a smear or a biopsy within the last three years are personally
invited for cytology-based cervical screening, as are women aged
50–65 years if they had no screening in the last five years. In 2010,
about 76% of women were screened within the recommended
interval [20]. The Department of Pathology, Hvidovre University
Hospital, is the largest cervical cytology laboratory in Denmark
receiving 66,000 LBC samples a year (2011). The laboratory
handles all primary and follow-up cervical samples from women
living in Copenhagen, which includes the Copenhagen and
Frederiksberg municipalities.
During the period from 10 June 2011 to 25 August 2011, a total
of 12,138 routine cervical samples were received at the laboratory.
On date of arrival, the samples were registered in the national
Pathology Data Bank using the Danish personal identification
number (CPR number) which includes the date of birth. Samples
were placed in racks of 48, and labeled with the woman’s CPR
number, a laboratory specimen identifier, and a barcode.
The present study, Horizon, was nested into the routine
laboratory practice. It utilized the residual material left in the vial
after SurePath-based LBC had been completed, and after any
postquot HC2 triage testing of samples with ASCUS diagnoses in
women aged $30 years. A total of 6,258 samples (52%) were
selected for the present study, taking the lowest rack numbers of
samples on testing days equally from Monday to Friday. Based on
capacity and processing considerations at the molecular biology
laboratory, the target number of samples was set to 5,000. A
maximum of 192 samples (four racks) were processed per day.
Samples with insufficient residual volume for further HPV testing
(n = 1,165) were excluded from the study. An additional 21
samples were excluded for technical reasons due to human error.
The final analysis of cobas testing could therefore be undertaken
on 5,072 samples (81% of those selected for the study). In
concordance with the protocol reviewed by the manufacturers
prior to the study, 2 ml of SurePath media was added to the
available residual material of approximately 2 ml (dilution factor
roughly 1:1), in order to obtain enough volume for additional
testing which will be reported separately. All testing was done in
the same laboratory.
In total, 5,013 samples (98.8%) were from unique women,
whereas the remaining 59 (1.2%) were collected from 29 women.
Women’s screening history from 1 January 2000 onwards was
ascertained from the nation-wide Danish Pathology Data Bank
[21]. Study samples with an earlier diagnosis of cervical cancer, or
a CIN diagnosis in the past three years were considered to be
follow-up samples. Likewise, samples with ASCUS in the previous
15 months, with more severe cytological abnormalities or with
a positive HPV test in the past 12 months were considered follow-
up samples. Other study samples were considered primary
samples. Reflecting routine cervical screening practice, primary
samples included screening samples and a small proportion of
samples taken by indication.
Cytology
Cytology screening of LBC samples was performed routinely
with a FocalPoint GS Imaging System (SlideWizard; BD,
Burlington, NC, USA). Cytological outcomes were reported
according to the Bethesda 2001 classification. They were classified
as ASCUS, low-grade squamous intraepithelial lesions (LSIL), or
high-grade squamous intraepithelial lesions or worse ($HSIL)
including atypical squamous cells – cannot exclude HSIL (ASC-
H), atypical glandular cells (AGC), adenocarcinoma in situ (AIS)
and carcinoma. Cytology was evaluated by cytoscreeners and
pathologists without knowledge of the outcomes of HPV testing.
Cobas HPV DNA Testing
For testing with cobas, 1 ml of the diluted material was
aliquoted into a 13 ml round bottom test tube (Sarstedt, cat. no
NC9018280). All tubes were labeled with the CPR number,
barcode and the laboratory specimen identifier used for cytology
testing. Subsequently, the tubes were stored at 2–8uC until testing
according to the manufacturer’s protocol. No pre-treatment of
SurePath samples was required. Extraction of DNA was un-
dertaken on the cobas x 480 instrument [22]. Amplification and
detection of high-risk HPV DNA were undertaken on the cobas z
480 analyzer. The real-time PCR platform amplified a sequence of
200 bp from the HPV L1 region using specific primers for the 14
targeted HPV genotypes, dNTP and the EagleZ05 DNA-Poly-
merase. Fluorescent TaqManH probes were used for detection of
the amplicons during PCR cycles. Amplification and detection of
the 330 bp b-globin was used as an internal control of the testing
processes. The end results were interpreted by the software as
‘‘negative’’, ‘‘HPV16’’, HPV18’’, ‘‘other high-risk HPV’’, or any
combination of the latter three. Samples with invalid results were
retested.
Additionally, we evaluated the intra-laboratory reproducibility
of the cobas assay. For this study, we used samples tested as part of
HPV Prevalence by Cobas Test on SurePath Samples
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the pre-trial validation of the cobas equipment during which
10.8% of the cobas samples returned invalid. We selected 200
negative and 300 positive cobas samples from different batches,
regardless of the women’s age, screening history or CT value.
After the pre-trial validation, the company calibrated the
instrumentation, resulting in a lower proportion of invalid samples
(0.1%) for the duration of the trial.
HC2 HPV DNA Testing
With HC2, the detection of 13 high-risk genotypes is done in
a bulk fashion with a ‘‘Positive’’ or ‘‘Negative’’ sample result
readout. The test has no internal control for sufficiency of test
material. Samples were either pretreated manually with DNA
denatured prior to testing according to the manufacturer’s
protocol, or DNA was isolated and purified using the DSP AXpH
DNA kit on the QIASymphony SP platform [23] (Qiagen, Hilden,
Germany). Testing of these samples was performed on automated
Rapid CaptureH System (Qiagen, Hilden, Germany) using scripts
depending on pretreatment. A minority of samples that were used
for triage of women with ASCUS were denatured and tested
manually as part of routine screening. Reading of results was
measured using the DML 2000TM Instrument with the digene
Hybrid Capture system version 2 software (DHCS v.2). Testing
was done on cytology postquot material.
Statistical Analysis
The outcomes of testing with cobas were reported hierarchically
(HPV16.HPV18.other high-risk HPV.negative.inadequate).
Positive cobas samples were defined in accordance with the
manufacturer’s critical threshold (CT) values, being #40.5 for
HPV16, #40.0 for HPV18, and #40.0 for other high-risk
genotypes, and positive HC2 samples as those with a relative
light unit per cut-off (rlu/co) value $1. Cytology was considered
abnormal if $ASCUS was reported. Differences in the distribu-
tions of age, screening history, cytology, and HC2 outcomes
between the included and excluded samples were tested with the
x2 test. The outcomes of the cobas testing were tabulated by the
age of the women, screening history (primary vs. follow-up
samples), cytology outcome, and the HC2 outcome. The trends in
HPV positivity by age were tested with the Mantel-Haenszel x2
test for trend, an 95% confidence intervals (CI) for relative risks
were calculated by assuming that their logarithms were approx-
imately normally distributed.
Ethical Considerations
This study was designed as a quality development study,
utilizing only residual material that would otherwise have been
anonymized and discarded. According to Danish regulations of
biomedical research, an ethical approval is not necessary for such
studies, in accordance with "Guidelines about Notification etc. of
a Biomedical Research Project to the Committee System on
Biomedical Research Ethics, No 9154, 5 May 2011, section 2.50.
Results
Between the 5,072 samples available for testing with cobas, and
the 1,186 samples that were excluded from the study, there were
no significant differences in the distributions by age group
(x2 = 11.2, df = 6, P = 0.084), cytology outcome (x2 = 3.58, df = 4,
P = 0.466), or HC2 outcome (x2 = 1.04, df = 1, P = 0.308). There
was a small but significant difference between the included and the
excluded samples in terms of the women’s screening history. In
total, 87.0% of the included samples, and 89.9% of the excluded
samples were primary samples (x2 = 7.29, df = 1, P = 0.007).
The mean number of days between the arrival of the sample in
the laboratory and storing was 2 (range: 1–5). The mean number
of days between storing and testing was 16 (range: 1–62). The
mean age of the women was 37.3 years (SD = 12.3, range: 16–89
years). In total, 162 (3.2%) samples were taken in women aged
below the recommended start of screening (23 years), and 113
(2.2%) in women aged above the recommended ending of
screening (65 years; Table 1). Reflecting a predominantly young
female population in the catchment area of the laboratory, 3,063
samples (60.4%) were taken in women aged 23–39 years.
Prevalence of HPV Infection
Of the 5,072 samples, 22 (0.4%) had to be retested, with three
(0.1%) remaining inadequate after retesting. Overall, 1,361
samples (26.8%) tested positive on cobas. Listing the HPV
genotypes hierarchically based on oncogenicity for cervical cancer
(HPV16.HVP18.12 other HR HPV genotypes.negative.ina-
dequate), single or multiple infections with genotype 16 were
detected in 365 (7.2%) samples; 130 (2.6%) samples showed single
or multiple infections with HPV genotype 18 excluding any
coinfections with HPV16; and the remaining 866 (17.1%) samples
showed single or multiple infections with any of the remaining
non-16/18 HPV genotypes targeted by the cobas assay.
For women targeted by the organized screening program (23–
65 years), the overall proportion testing positive on the cobas
assay decreased with age from 43.1% in women aged 23–29
years to 10.3% in women aged 60–65 years (Table 1; P for
trend ,0.0001). This trend was equally strong for HPV16,
HPV18 and the bulk of other 12 high risk HPV genotypes (all
P values for trend ,0.0001). For comparison, the proportion of
women aged 23–29 years testing positive on HC2 was 33.0%,
whereas 17.4% tested positive at age 30–39 years, 11.3% at age
40–49 years, 7.3% at age 50–59 years, and 6.0% at age 60–65
years. The proportion of samples taken from women aged 16–
22 years testing positive on the cobas assay was 63.0%. This
could possibly be a consequence of presentation of women for
a medical condition or of self-selection for screening as routine
screening is not offered at this age. After age 60 years, the
detection of HPV infections appeared to increase, however, the
number of tested samples was small.
Only 373 (7.4%) samples were abnormal on cytology. Among
women with normal cytology, 22.9% of the samples tested positive
on cobas and 15.6% on HC2. Among women with ASCUS, these
proportions were 63.4% for cobas and 64.2% for HC2; they were
79.7% and 89.5%, respectively, for LSIL; and 88.8% and 90.7%,
respectively, for $HSIL.
These results were fairly similar for the subgroup of 4,413
primary tests (Table 2). In total, 1,081 (24.5%) of primary samples
taken at any age would test positive if the cobas assay was used as
the primary screening test (Figure 1). Now that cytology is used as
a primary screening test, 242 (5.5%) samples tested positive. For all
ages combined 182 (4.1%) of primary samples were positive on
both the cobas assay and LBC. As the proportions of samples
positive on the cobas assay varied considerably by age, so did the
proportions of samples positive on cobas with normal cytology.
Across all age groups, 898 of 4,413 (20.3%) samples were cobas
HPV positive with normal cytology, but this proportion decreased
from 33.9% in women aged 23–29 years to 18.6% at age 30–39
years (relative risk compared to 23–29 years: 0.55, 95% CI: 0.48–
0.63), 11.5% at age 40–49 years (relative risk compared to 23–29
years: 0.34, 95% CI: 0.28–0.41), and 6.0% at age 50–65 years
(relative risk compared to 23–29 years: 0.18, 95% CI: 0.13–0.24, P
for trend ,0.0001).
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Intra-laboratory Reproducibility of the Cobas Assay
Among the 300 samples that tested positive on the initial cobas
run, 272 (90.7%) tested positive also in the second run. Among the
28 (9.3%) samples that changed from positive to negative, the
average CT value was 38.0 (range: 16.3–40.1) in the first run, and
19 were uniquely positive for ‘‘other high-risk genotypes’’. Among
the 200 samples that tested negative on the initial cobas run, 196
(98.0%) tested negative in the second run, whereas 4 (2.0%)
changed the outcome from negative to positive. The average CT
value of the latter samples was 39.3 (range: 38.8–40.0) in the
second run, suggesting weakly positive HPV samples.
Discussion
Main Findings
In Copenhagen, where the background risk of cervical cancer
has been high, 27% of women tested positive for the bulk of 14
high-risk HPV genotypes included in the cobas assay. Even in
samples without recent cervical abnormalities, 24% tested positive.
As expected, this was considerably higher than the 7% and 5% of
women, respectively, with abnormal cytology. The proportions of
women testing positive on cobas decreased from 43% (41%) in
women aged 23–29 years to 10% (9%) in women aged 60–65
years. About two-thirds of the positive cobas tests were due to
genotypes other than HPV16 and HPV 18. This is not unusual, as
infections with these HPV genotypes are frequent in women with
normal cytology or with low-grade CIN [24,25], though they only
cause about one-third of cervical cancers [9].
In line with the higher prevalence of HPV genotypes 16 and 18
in high-grade lesions, 52% of cytological $HSIL in our study
showed an infection with these two genotypes. However, we found
that 11% of samples with $HSIL on cytology (0.2% of all samples)
tested negative on the cobas assay. In the Danish screening
program, women with $HSIL are currently referred for
colposcopy without HPV DNA triage. We will monitor them
through linkage with the Pathology Data Bank to determine
whether HPV triage could be used to reduce false-positive referrals
for colposcopy.
More surprising was the fact that the proportion of positive
samples was 27% for cobas versus 20% for HC2. Some of this
difference may be due to the differences in the designs of the
assays. While the cobas was designed to detect 14 HPV types,
HC2 was designed to detect 13 HPV types. Furthermore, cobas is
a real-time PCR-based L1 DNA assay, whereas HC2 is an RNA to
DNA hybridization assay.
Although using samples from the pre-trial validation of the
cobas instrumentation, the intra-laboratory reproducibility of
negative cobas results was high. The 2.0% of the initially
negative samples that tested positive in the second run showed
very high average CT values. This is reassuring given the on-
going international discussions on extending the screening
interval. However, the 90.7% reproducibility of the initially
positive cobas results suggests that the calibration of the probe
for ‘‘other high-risk genotypes’’ is not highly robust. In a Dutch
validation study using Universal Collection Medium, the intra-
laboratory positive reproducibility of the cobas assay was 97.3%
[26], suggesting that the choice of the SurePath media could in
part explain the low positive reproducibility of the cobas assay
in our study.
Strengths and Weaknesses
Our study was population-based and used consecutive samples
from a large public laboratory. Nineteen percent of the selected
samples had to be discarded because only small amounts of
Figure 1. Primary cervical samples, by age and outcome of cytology and HPV testing with cobas.
doi:10.1371/journal.pone.0059765.g001
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residual material were available for the study. There was no
significant difference between the included and the excluded
samples in terms of the age of the women, cytology interpretation,
and the HC2 outcome. All samples were tested in one laboratory
by the same staff that is involved in routine screening. The
proportion of women aged 25–64 years without recent abnormal-
ities who tested positive on the HC2 assay, 16%, was similar to
that observed in an earlier study covering the same catchment
area, approximately 17% [27]. The 5,072 tested samples can
therefore be considered as highly representative for the study
population.
The cobas assay, furthermore, functioned well on the diluted
SurePath media, as only 3 (0.1%) out of 5,072 samples had an
inadequate outcome. Our study is the first to report the cobas
outcomes based on SurePath samples. SurePath has an estimated
market share in England of about 55%, 70% in Denmark (Ole
Jakobsen, Axlab, personal communication, 2012), and about 30%
in the USA [28]. Previous studies of the cobas assay used samples
stored in PreservCyt [11,14–17,29–32], specimen transport
medium [18], or universal collection medium [26]. SurePath
contains 0.1% formaldehyde as a fixative which may eliminate
enzymatic activity, so the outcomes of HPV testing may vary by
transport media.
Following the standard recommendations within the Danish
cervical screening program, women in our study population with
abnormal cytology were referred for colposcopy or for repeated
testing. As a follow-up to the current study, we will additionally
invite women with positive HPV tests and normal cytology for
repeated testing in 12 months. The standard measures of
sensitivity and specificity of the screening tests will be reported
once the histological follow-up of the study population has been
completed.
Comparison with Previous Studies
The cobas assay was FDA-approved based on the ATHENA
study which included women presenting for routine screening
[11]. The proportion of women aged 25–59 years with abnormal
primary cytology was slightly higher in ATHENA, 6.5%, than in
our study, 5.0%, standardized to match the age distribution in the
ATHENA study. This difference derived from women aged below
50 years, whereas no difference was found for women aged 50–59
years. The higher cytology abnormality proportion in the USA
compared to Denmark could be explained by differences in the
background risk of cervical cancer, and in the interpretation of
cytology, especially in pre-menopausal women. On the other
hand, the age-standardized proportion of women with positive
cobas samples was lower in ATHENA than in our study, 10.8%
vs. 19.4%, respectively, again as a result of differences among
women below age 50 years. The higher HPV-positivity proportion
in our study could reflect technical differences deriving from
comparison of PreservCyt with SurePath samples, or it could
reflect a higher prevalence of HPV infection. Concerning
technical differences, one would then expect equal differences
across age-groups, but this was not the case. Therefore, the
difference is most likely a consequence of a higher prevalence of
HPV infections in the Danish compared to the USA population.
Consequently, for women aged 25–59 years the gap between the
proportion of positive cobas samples and the proportion of
abnormal cytology was more than twice as large in our study as in
ATHENA (3.9 vs. 1.7, respectively). This stresses the need for local
trial data before decisions on future screening tests are taken on
regional or national level.
Several studies evaluated the use of the cobas assay among
women referred for colposcopy because of abnormal cytology. The
Predictors 2 study compared the cobas assay to three other HPV
DNA assays (HC2, Abbott RealTime, and BD HPV test), two
HPV mRNA assays (Gen-Probe APTIMA, Norchip Proofer), and
one immunocytochemical assay (MTM CINtec p16INK4a) in 1,099
women [14]. Cobas was among the most sensitive tests for
$CIN3, however not among the most specific for $CIN2. In the
‘‘Early Evaluator Program’’ study undertaken on a convenience
sample of 1,360 women from Spain, France and Italy primarily
presenting for follow-up of an earlier abnormality, 87% of samples
were concordant on cobas and HC2. However, among the
discordant samples those negative on cobas were more likely to
show infections with low-risk HPV genotypes, whereas among
those positive on cobas a larger proportion showed infections with
high-risk HPV genotypes [32]. This distinction was corroborated
in a study of 1,852 women from the USA retested one year after
positive HC2 results [18], but not in 472 women presenting for
routine LBC in Canada [29].
Implications for Screening
Because of the high proportions of young women testing
positive, HPV DNA testing has been proposed from age 30 or 35
years onwards. In our study, primary samples (including a small
proportion of samples taken by indication, reflecting the routine
running of the Danish screening program) of 16.2% of women
aged 30–65 years tested positive on cobas, and 2.8% of women
had both a positive cobas test and abnormal cytology (Figure 1). In
contrast, 4.4% of women at this age had abnormal primary
cytology. Based on historical data from the laboratory, 1.3% of
screened women had abnormal cytology and $CIN3 detected in
the follow-up. Assuming that HPV DNA testing is 32% more
sensitive for $CIN3 than cytology [1], about 1.7% of women
would be expected to have a positive cobas test and a $CIN3
lesion. Thus, with primary HPV DNA testing with the cobas assay,
about 14.5% (16.2% positive on cobas 21.7% as the expected
$CIN3 detection rate) of screened women would have a $CIN3
false-positive test, whereas with cytology-based screening this is
now about 3.1% ( = 4.4% abnormal cytology 21.3% as the
expected $CIN3 detection rate on cytology).
Much work has been done to define optimal criteria for referral
of HPV-positive women for colposcopy [10,33]. In our study,
2.8% of women aged 30–65 years could be immediately referred
for colposcopy if cytology $ASCUS was set as the threshold for
HPV-positive samples. This means that the remaining 13.4%
( = 16.2% positive on cobas 22.8% positive on cobas and
cytology) of women would be followed-up initially with repeated
testing. However, this proportion might vary across settings. In the
ATHENA trial, it was 6.7% for women above age 30 years [13].
Reducing the extent of repeated testing is a priority issue for
introducing HPV DNA-based primary screening. Countries with
a high prevalence of HPV infection such as Denmark should
therefore proceed to HPV-based primary cervical screening with
caution because the extent of follow-up testing and diagnostics
could be enormous whether or not triage is used to refer women
for colposcopy.
Conclusions
Our study showed a 27% high-risk HPV positivity proportion
when unselected women from Copenhagen were tested with the
cobas assay, and 20% when tested with HC2. These positivity
rates were far above the 7% abnormality rate found in routine
cytology screening. Even in women without recent abnormalities
aged $30 years these percentages were 16% and 4%,
respectively.
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